65,470 Shares in Jazz Pharmaceuticals PLC $JAZZ Purchased by Aberdeen Group plc

Aberdeen Group plc purchased a new position in Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) during the third quarter, according to its most recent Form 13F filing with the SEC. The fund purchased 65,470 shares of the specialty pharmaceutical company’s stock, valued at approximately $8,629,000. Aberdeen Group plc owned approximately 0.11% of Jazz Pharmaceuticals at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in the business. Kennedy Capital Management LLC purchased a new stake in shares of Jazz Pharmaceuticals in the second quarter worth about $1,100,000. Wedge Capital Management L L P NC acquired a new position in Jazz Pharmaceuticals in the third quarter valued at approximately $27,834,000. Essex Investment Management Co. LLC purchased a new stake in Jazz Pharmaceuticals in the 3rd quarter worth approximately $2,697,000. Sequoia Financial Advisors LLC purchased a new stake in Jazz Pharmaceuticals in the 3rd quarter worth approximately $605,000. Finally, Measured Wealth Private Client Group LLC grew its stake in shares of Jazz Pharmaceuticals by 47.1% during the 2nd quarter. Measured Wealth Private Client Group LLC now owns 4,855 shares of the specialty pharmaceutical company’s stock worth $515,000 after purchasing an additional 1,554 shares during the period. 89.14% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of research analysts have weighed in on the stock. Wells Fargo & Company upped their price objective on shares of Jazz Pharmaceuticals from $170.00 to $235.00 and gave the stock an “overweight” rating in a research report on Tuesday, November 18th. Robert W. Baird increased their price target on Jazz Pharmaceuticals from $160.00 to $209.00 and gave the stock an “outperform” rating in a research report on Tuesday, November 18th. JPMorgan Chase & Co. dropped their price objective on Jazz Pharmaceuticals from $204.00 to $199.00 and set an “overweight” rating on the stock in a report on Monday, October 27th. Royal Bank Of Canada set a $194.00 target price on Jazz Pharmaceuticals and gave the stock an “outperform” rating in a research note on Monday, November 17th. Finally, UBS Group reissued a “neutral” rating and issued a $188.00 price target (up previously from $163.00) on shares of Jazz Pharmaceuticals in a research note on Monday, November 24th. Fourteen equities research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $205.67.

Jazz Pharmaceuticals Stock Up 0.5%

Jazz Pharmaceuticals stock opened at $169.59 on Friday. The firm has a market capitalization of $10.30 billion, a P/E ratio of -27.94, a P/E/G ratio of 0.91 and a beta of 0.26. The company has a current ratio of 1.65, a quick ratio of 1.44 and a debt-to-equity ratio of 1.09. Jazz Pharmaceuticals PLC has a twelve month low of $95.49 and a twelve month high of $182.99. The stock’s fifty day simple moving average is $167.83 and its 200-day simple moving average is $148.46.

Insider Activity

In related news, SVP Mary Elizabeth Henderson sold 2,238 shares of the business’s stock in a transaction on Tuesday, December 9th. The shares were sold at an average price of $169.51, for a total transaction of $379,363.38. Following the completion of the transaction, the senior vice president owned 19,508 shares in the company, valued at approximately $3,306,801.08. The trade was a 10.29% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Bruce C. Cozadd sold 77,500 shares of Jazz Pharmaceuticals stock in a transaction dated Wednesday, November 26th. The stock was sold at an average price of $177.81, for a total value of $13,780,275.00. Following the sale, the director directly owned 393,332 shares of the company’s stock, valued at $69,938,362.92. This trade represents a 16.46% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last three months, insiders have sold 84,398 shares of company stock worth $14,957,430. 4.30% of the stock is currently owned by corporate insiders.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing therapies in neuroscience and oncology. The company’s research and development efforts target unmet medical needs in sleep disorders, hematologic malignancies, rare neurological conditions and solid tumors. Jazz’s product portfolio includes therapies for narcolepsy, hepatic veno-occlusive disease, acute myeloid leukemia and other serious disorders.

Flagship products from Jazz Pharmaceuticals include Xyrem® (sodium oxybate) and Xywav® (calcium, magnesium, potassium, and sodium oxybates) for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy.